EPIC Early Detection of Ovarian Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 27418634.
- Also identified by DOI 10.1158/1078-0432.CCR-16-1391 and PMC identifier 5026579.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CA125 dominated performance for ovarian cancer early detection among four serum biomarkers evaluated in EPIC study prediagnostic serum, rising on average 3 years prior to detection. Adding HE4 provided only marginal improvement. This natural history supports annual testing for early detection and highlights the importance of biomarker discovery complementing CA125. Clin Cancer Res; 22(18); 4542-4. ©2016 AACRSee related article by Terry et al., p. 4664.
Medical subject headings
- Biomarkers, Tumor
- Early Detection of Cancer
- Ovarian Neoplasms